Further, we evaluated the activity of our BCL-XL PROTAC degrader DT2216 on the viability of these SCLC cell lines where 50% (10/20) cell lines were found to be sensitive to DT2216 with an EC50 of <1 μM. This evidence concerns the gene BCL2L1 and small cell lung carcinoma.